Update shared on 03 Nov 2025
Fair value Increased 1.12%Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.
What's in the News
- Launched the ProximityScope assay, a spatial solution for visualizing protein-protein interactions on fixed tissue. This enables enhanced discovery and translational research (Product-Related Announcements).
- Formed a new distribution agreement with Saguaro Biosciences to expand global access to Saguaro's non-toxic, wash-free dyes. This move targets the growing need for advanced cell-based assay reagents (Client Announcements).
- Enhanced collaboration with Oxford Nanopore Technologies to broaden the development of genetic products and extend the partnership through 2032, with a focus on heritable genetic disorder screening (Strategic Alliances).
- Advanced spatial biology portfolio with RNAscope ISH technology and Lunaphore COMET, further supporting integrated detection of RNA and protein biomarkers in diagnostic workflows (Product-Related Announcements).
- Dropped from the FTSE All-World Index (Index Constituent Drops).
Valuation Changes
- Fair Value Estimate has risen slightly from $67.08 to $67.83. This reflects a modestly more positive outlook.
- Discount Rate increased marginally from 7.35% to 7.37%. This indicates a slightly higher perceived risk or required return.
- Revenue Growth projection has fallen slightly, moving from 5.88% to 5.81%.
- Net Profit Margin has improved modestly, increasing from 17.28% to 17.30%.
- Future P/E Ratio has edged up from 48.10x to 48.70x, signifying a modest change in valuation expectations.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.